AMNOG Benefit Dossiers According to § 35a SGB V
Germany has gone through a major regulatory change.
AMNOG Benefit Dossiers according to § 35a SGB V
The Pharmaceutical Market Restructuring Act (AMNOG) and the resulting requirements for benefit assessment according to § 35a SGB V have changed the conditions of market access and the pricing of pharmaceuticals fundamentally in Germany. This new regulation applies to newly approved and already existing pharmaceuticals.
We develop entire Benefit Dossiers or specific parts for an existing Benefit Dossier.
We offer strategic consulting and support in developing a Benefit Dossier, as well as professional review of existing Benefit Dossiers.